BioSpace News Archive

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, announced the grant of inducement awards to three new employees.

Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will present at the 23rd Annual Needham Virtual Healthcare Conference at 11am EDT on April 8, 2024.

Olema Pharmaceuticals, Inc. announced that the Company granted stock options to two new employees to purchase an aggregate of 60,000 shares of the Company’s common stock, effective as of April 1, 2024.

FibroGen, Inc. announced topline data from the Fortis Therapeutics-sponsored Phase 1 study of FG-3246, a potential first-in-class anti-CD46 antibody drug conjugate with an MMAE-containing payload, in a dose-escalation and dose-expansion trial enrolling patients with metastatic castration-resistant prostate cancer whose tumors have progressed on at least one androgen receptor-signaling inhibitor.

StageZero Life Sciences, Ltd. announced a delay in the filing of its audited consolidated financial statements for the year ended December 31, 2023, management’s discussion and analysis for the same period and management certifications of annual filings beyond the deadline of April 2, 2024 prescribed by Canadian securities laws.

Convergent Therapeutics Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has cleared the investigational new drug (“IND”) application for CONV01-α, its lead candidate for the treatment of patients with advanced prostate cancer.

Cytokinetics, Incorporated announced that on March 29, 2024 it granted stock options to purchase an aggregate of 78,000 shares of common stock to five new employees, whose employment commenced in March 2024, as a material inducement to their employment.

GV20 Therapeutics, a clinical-stage biotechnology company integrating AI, genomics, and disease biology to create next-generation antibody therapeutics for cancer, announced today that it will present at the Needham 23rd Annual Virtual Healthcare Conference, taking place April 8-11, 2024.

Sight Sciences, Inc. (Nasdaq: SGHT) announced today that data from studies of two of its proprietary glaucoma and dry eye technologies, the OMNI Surgical System (“OMNI”) and the TearCare System (“TearCare”), will be presented in two oral presentations and two posters at this year’s ASCRS Annual meeting April 5th to 8th in Boston, MA.

LENZ Therapeutics, Inc. today announced that the Company will host a conference call and webcast on Wednesday, April 3, 2024, at 8:00 a.m. ET to discuss the topline results from its Phase 3 CLARITY study, a group of three multi-center, double-masked, randomized active and vehicle-controlled clinical trials evaluating the efficacy and safety of two investigational formulations of aceclidine, LNZ100 and LNZ101, for the treatment of presbyopia.